Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
34.17
-1.18 (-3.34%)
Apr 30, 2026, 9:25 AM CST
SHE:002940 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 156.73 | 80.33 | 138.37 | 127.3 | 119.84 |
Depreciation & Amortization | 77.06 | 87.23 | 78.78 | 61.1 | 46.36 |
Other Amortization | 1.76 | 2.12 | 1.71 | 0.67 | 0.77 |
Loss (Gain) From Sale of Assets | 0.03 | 0.01 | 0.04 | 0 | -0 |
Asset Writedown & Restructuring Costs | 5.94 | 2.92 | 1.96 | 5.94 | 3.5 |
Loss (Gain) From Sale of Investments | 17.43 | 5.15 | 0.32 | 1.86 | 8.38 |
Provision & Write-off of Bad Debts | - | -0.28 | -1.53 | - | - |
Other Operating Activities | 1.28 | 76.79 | 69.77 | 9.81 | 22.42 |
Change in Accounts Receivable | -27.17 | 11.35 | 86.63 | -47.82 | -39.99 |
Change in Inventory | 50.36 | -118.77 | -23.82 | 2.06 | -25.15 |
Change in Accounts Payable | -49.53 | 125.75 | -84.13 | 21.96 | 57.57 |
Change in Other Net Operating Assets | 0.93 | -0.06 | 9.34 | 2.11 | 1.8 |
Operating Cash Flow | 244.13 | 253.6 | 276.91 | 184.75 | 197.65 |
Operating Cash Flow Growth | -3.73% | -8.42% | 49.89% | -6.53% | -0.48% |
Capital Expenditures | -49.94 | -94.46 | -124.95 | -68.82 | -87.32 |
Sale of Property, Plant & Equipment | 0.22 | 1.87 | 0.5 | 0.21 | 0.38 |
Cash Acquisitions | - | - | -117.48 | - | 4.98 |
Investment in Securities | -60.62 | -372.68 | 67.91 | -453.36 | -151.4 |
Other Investing Activities | 24.36 | 3.36 | 4.02 | 0.65 | 0.56 |
Investing Cash Flow | -85.98 | -461.91 | -170.01 | -521.32 | -232.8 |
Long-Term Debt Issued | 191.71 | 457.57 | 545.95 | 372.89 | 2 |
Total Debt Issued | 191.71 | 457.57 | 545.95 | 372.89 | 2 |
Long-Term Debt Repaid | -227.92 | -559.87 | -383.72 | -27.99 | -12 |
Total Debt Repaid | -227.92 | -559.87 | -383.72 | -27.99 | -12 |
Net Debt Issued (Repaid) | -36.21 | -102.3 | 162.23 | 344.9 | -10 |
Issuance of Common Stock | - | - | - | 63.32 | - |
Repurchase of Common Stock | - | -54.38 | -20.12 | - | -63.34 |
Common Dividends Paid | -57.6 | -58.77 | -61.62 | -34.16 | -47.06 |
Other Financing Activities | -65.94 | -97.99 | -64.85 | 2.55 | -3.2 |
Financing Cash Flow | -159.75 | -313.44 | 15.65 | 376.62 | -123.6 |
Foreign Exchange Rate Adjustments | 0.35 | 7.21 | 1.16 | 1.27 | -0.58 |
Net Cash Flow | -1.24 | -514.53 | 123.72 | 41.32 | -159.33 |
Free Cash Flow | 194.19 | 159.14 | 151.96 | 115.92 | 110.33 |
Free Cash Flow Growth | 22.02% | 4.72% | 31.09% | 5.07% | 2.49% |
Free Cash Flow Margin | 13.63% | 10.52% | 9.38% | 7.39% | 7.99% |
Free Cash Flow Per Share | 0.96 | 0.79 | 0.76 | 0.58 | 0.55 |
Cash Interest Paid | - | 0.1 | 0.1 | 0.1 | 0.1 |
Cash Income Tax Paid | 76.83 | -4.4 | 45.91 | 64.32 | 141.61 |
Levered Free Cash Flow | 171.34 | 78.78 | -15.38 | 57.79 | 26.09 |
Unlevered Free Cash Flow | 171.34 | 89.15 | -6.52 | 61.78 | 26.32 |
Change in Working Capital | -16.09 | -0.69 | -12.5 | -21.93 | -3.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.